- Issuer ticker
-
ABCL
- Reported as of
-
10 Dec 2021
- Net transaction value
-
+$160,000
Source evidence
Original filing metadata and source links for verification.
5 source fields
- SEC form
-
4
- Accepted by SEC
-
10 Dec 2021, 16:00:14 UTC
Reporting owner
1 detail
- Reporting owner signature
-
/s/ Tryn Stimart, attorney-in-fact
Key filing fact
Andrew Booth filed Form 4 for AbCellera Biologics Inc. (ABCL) on 10 Dec 2021.
Key facts
- This page summarizes Andrew Booth's Form 4 filing for AbCellera Biologics Inc. (ABCL).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 10 Dec 2021, 16:00.
Change
- Previous filing in this sequence was filed on 09 Dec 2021.
- Current net transaction value: +$160,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ABCL
transaction
Common Shares
Options Exercise
- Transaction value
- $160,000
- Shares
- +500,000
- Change %
- +935%
- Price
-
$0.3200*
- Shares after
- 553,500
- Date
- 10 Dec 2021
- Ownership
- Direct
ABCL
holding
Common Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
-
- Shares after
- 130,959
- Date
- 10 Dec 2021
- Ownership
- By spouse
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ABCL
transaction
Derivative
Share Options (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -500,000
- Change %
- -8.5%
- Price
-
$0.000000
- Shares after
- 5,384,820
- Date
- 10 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 500,000
- Exercise price
- $0.3200
* marks a reported price that did not pass the local price check.